CN
Search Within
F-017
应用筛选条件
关键词:'F-017'
显示 1-30 共 34 条结果 关于 "F-017" 范围 论文
Nian Liu et al.
Trends in cardiovascular medicine, 22(2), 35-39 (2012-08-08)
Recent studies have shown that flecainide may be an effective therapy to prevent life-threatening arrhythmias in patients with catecholaminergic polymorphic ventricular tachycardia. Several hypotheses have been advanced to explain the antiarrhythmic mechanism of flecainide, including Na(+) channel blockade and a
C Cros et al.
Toxicology and applied pharmacology, 265(2), 200-208 (2012-10-18)
Drugs slowing the conduction of the cardiac action potential and prolonging QRS complex duration by blocking the sodium current (I(Na)) may carry pro-arrhythmic risks. Due to the frequency-dependent block of I(Na), this study assesses whether activity-related spontaneous increases in heart
[Flecainide intoxication].
Santiago Nogué et al.
Medicina clinica, 140(1), 46-46 (2012-10-03)
Kosuke Doki et al.
Pharmacogenetics and genomics, 22(11), 777-783 (2012-09-04)
To investigate the association between age-related decline in flecainide clearance and CYP2D6 genotype, we conducted a population pharmacokinetic analysis of flecainide using routine therapeutic drug monitoring data. Population pharmacokinetic analysis was performed on retrospective data from 163 genotyped patients treated
Jens Cosedis Nielsen et al.
The New England journal of medicine, 367(17), 1587-1595 (2012-10-26)
There are limited data comparing radiofrequency catheter ablation with antiarrhythmic drug therapy as first-line treatment in patients with paroxysmal atrial fibrillation. We randomly assigned 294 patients with paroxysmal atrial fibrillation and no history of antiarrhythmic drug use to an initial
Heather Ellsworth et al.
Pacing and clinical electrophysiology : PACE, 36(3), e87-e89 (2012-08-14)
Flecainide is a Vaughan Williams Class Ic antidysrhythmic associated with PR, QRS, and QTc prolongation on the electrocardiogram and development of life-threatening cardiac toxicity in overdose. The cornerstone of treatment is fluid resuscitation and the administration of magnesium and sodium
G Cave et al.
Clinical toxicology (Philadelphia, Pa.), 51(5), 394-397 (2013-05-25)
The use of intravenous lipid emulsion (ILE) as an antidote in non-local, anaesthetic drug toxicity has generated considerable interest. Flecainide is a lipophilic anti-arrhythmic with a significant cardiotoxic profile, with blockade of sodium and potassium channels causing arrhythmias and shock
Nancy M Allen LaPointe et al.
The American journal of cardiology, 115(3), 316-322 (2014-12-11)
Little is known in clinical practice about antiarrhythmic drug (AAD) use in patients with atrial fibrillation (AF) (particularly younger ones) who do not have structural heart disease. Using the MarketScan database, we identified patients <65 years without known coronary artery disease
Joseph J Lynch et al.
Journal of cardiovascular pharmacology, 61(3), 226-232 (2012-11-29)
This study explored the intrinsic vasorelaxant and inotropic effects of the mixed potassium and sodium channel blocker atrial antiarrhythmic vernakalant and the class IC antiarrhythmic agent flecainide in human isolated subcutaneous resistance artery and in ventricular trabecular muscle preparations. At
Cecile Terrenoire et al.
The Journal of general physiology, 141(1), 61-72 (2013-01-02)
Understanding the basis for differential responses to drug therapies remains a challenge despite advances in genetics and genomics. Induced pluripotent stem cells (iPSCs) offer an unprecedented opportunity to investigate the pharmacology of disease processes in therapeutically and genetically relevant primary
Lovely Chhabra et al.
Indian heart journal, 64(4), 404-407 (2012-08-30)
Flecainide (a class 1c antiarrhythmic) produces a dose-dependent decrease in intracardiac conduction. Its well known common electrocardiographic effects are prolongation of PR and QT intervals and the QRS complex duration. We report a case of flecainide toxicity in an elderly
Jean-François Desaphy et al.
Experimental neurology, 255, 96-102 (2014-03-13)
Although the sodium channel blocker mexiletine is considered the first-line drug in myotonia, some patients experiment adverse effects, while others do not gain any benefit. Other antimyotonic drugs are thus needed to offer mexiletine alternatives. In the present study, we
David H Jang et al.
The Journal of emergency medicine, 44(4), 781-783 (2012-09-18)
Flecainide is a class IC antidysrhythmic primarily indicated for ventricular dysrhythmias and supraventricular tachycardia (SVT). Class IC antidysrhythmic overdose has a reported mortality of 22%, and death results from dysrhythmias and cardiovascular collapse. We report a near-fatal flecainide overdose in
ECG diagnosis: flecainide toxicity.
Joel T Levis
The Permanente journal, 16(4), 53-53 (2012-12-20)
Antiarrhythmic drug treatment after cardioversion of atrial fibrillation.
Marcelle D Smit et al.
Lancet (London, England), 380(9852), 1467-1467 (2012-10-30)
Treatment for patients with catecholaminergic polymorphic ventricular tachycardia: are we in need of randomized trials?
Arthur A M Wilde et al.
Journal of electrocardiology, 45(6), 739-740 (2012-07-31)
Antiarrhythmic drug treatment after cardioversion of atrial fibrillation.
Ajay Vallakati et al.
Lancet (London, England), 380(9852), 1467-1468 (2012-10-30)
Martial Massin et al.
Acta cardiologica, 68(5), 513-515 (2013-11-29)
A giant cardiac fibroma was discovered during evaluation for a soft systolic murmur in an asymptomatic 2-week-old girl. Echocardiography and magnetic resonance imaging showed a large intraventricular solid mass developed at the expense of the left ventricular lateral wall. Tumour
D Mehra et al.
Molecular pharmacology, 86(6), 696-706 (2014-10-03)
Catecholaminergic polymorphic ventricular tachycardia (CPVT) causes sudden cardiac death due to mutations in cardiac ryanodine receptors (RyR2), calsequestrin, or calmodulin. Flecainide, a class I antiarrhythmic drug, inhibits Na(+) and RyR2 channels and prevents CPVT. The purpose of this study is
Damineh Morsali et al.
Brain : a journal of neurology, 136(Pt 4), 1067-1082 (2013-03-23)
Axonal degeneration is a major cause of permanent disability in the inflammatory demyelinating disease multiple sclerosis, but no therapies are known to be effective in axonal protection. Sodium channel blocking agents can provide effective protection of axons in the white
Dag S Thelle et al.
Heart (British Cardiac Society), 99(23), 1755-1760 (2013-06-12)
To study the impact of resting heart rate and leisure time physical activity at middle age on long term risk of drug treated lone atrial fibrillation (AF). Longitudinal cohort study of 309 540 Norwegian men and women aged 40-45 years
Flecainide or propafenone vs. vernakalant for conversion of recent-onset atrial fibrillation.
Diego Conde et al.
The Canadian journal of cardiology, 29(10), 1330-1330 (2013-03-08)
[CME ECG 40. Vertigo with ST elevation in V2. Brugada syndrome].
Ardan M Saguner et al.
Praxis, 102(5), 305-307 (2013-03-01)
Conversion of recent onset atrial fibrillation: which drug is faster?
Diego Conde
The American journal of emergency medicine, 31(9), 1410-1411 (2013-06-26)
Tianxing Wang et al.
Biosensors & bioelectronics, 49, 9-13 (2013-05-28)
Drug-induced cardiotoxicity greatly endangers the human health and results in resource waste. Also, it is a leading attribution to drug withdrawal and late-stage attrition in pharmaceutical industry. In the study, a dual function cardiomyocyte-based biosensor was introduced for rapid drug
Marina Cerrone et al.
Cardiovascular research, 95(4), 460-468 (2012-07-06)
The shRNA-mediated loss of expression of the desmosomal protein plakophilin-2 leads to sodium current (I(Na)) dysfunction. Whether pkp2 gene haploinsufficiency leads to I(Na) deficit in vivo remains undefined. Mutations in pkp2 are detected in arrhythmogenic right ventricular cardiomyopathy (ARVC). Ventricular
Stavros Apostolakis et al.
Expert opinion on pharmacotherapy, 14(3), 347-357 (2013-01-09)
Flecainide is a class Ic antiarrhythmic agent available in Europe since 1982. The clinical development program of flecainide provided good data on its antiarrhythmic effect for the prevention of ventricular and supraventricular arrhythmias. The Cardiac Arrhythmia Suppression Trial (CAST), conducted
Luiz Belardinelli et al.
The Journal of pharmacology and experimental therapeutics, 344(1), 23-32 (2012-09-27)
Inhibition of cardiac late sodium current (late I(Na)) is a strategy to suppress arrhythmias and sodium-dependent calcium overload associated with myocardial ischemia and heart failure. Current inhibitors of late I(Na) are unselective and can be proarrhythmic. This study introduces GS967
A misguided 'pill in the pocket' approach with flecainide leading to cardiac arrest.
Daniel Kiblboeck et al.
BMJ case reports, 2012, doi:10-doi:10 (2012-08-29)
Thomas Lloyd et al.
The American journal of emergency medicine, 31(9), 1418-1418 (2013-07-03)
An 82-year-old white woman was seen in the emergency department (ED) after ingesting 400 mg of flecainide in an attempt to treat an episode of dizziness and palpitations that occurred while she was gardening. Consequently, she developed bradycardia, hypotension, and
1/2